Fennec Pharmaceuticals (FENC) investor relations material

Executive summary

• Achieved seventh consecutive quarter of growth, with Q2 2026 net product sales up 78% year-over-year to $17.1 million, driven by expanded commercial reach and increased demand for PEDMARK® in pediatric and AYA populations.

• Presented new real-world evidence at ASCO 2026 supporting PEDMARK®'s integration into patient care without compromising cisplatin's antitumor activity.

• Maintained strong cash position of $41.2 million as of June 30, 2026, with management confident in funding the current operating plan.

• Expanded commercial and medical teams, increasing prescriber targets and field sales efforts, and launched innovative disease awareness campaigns.

Financial highlights

• Net product sales reached $17.1 million in Q2 2026, up from $9.7 million in Q2 2025, with non-GAAP adjusted EBITDA of $2.8 million and net income of $2.0 million.

• EPS improved to $0.06 basic and $0.05 diluted per share, compared to a loss of $0.11 per share year-over-year.

• Cash and cash equivalents stood at $41.2 million as of June 30, 2026, up from $36.8 million at December 31, 2025.

• Operating expenses increased to $16.1 million in Q2 2026, primarily due to higher selling and marketing costs.

• Gross margin remained strong as cost of product sales decreased despite higher revenues.

Outlook and guidance

• Management expects continued sequential growth in Q3 and Q4, with record demand and patient enrollments in July.

• Anticipates current cash, equivalents, and projected revenues will be sufficient to fund operations under the current plan.

• Considering providing formal revenue guidance for 2027 as business stabilizes.

• Ongoing investigator-sponsored studies and additional market launches in Europe are expected to support future growth.